Join our experts for a short discussion on the future of the PARP inhibitors, a potential new class of anticancer agents that are back in the spotlight following the ASCO meeting.
Your expert hosts for this session:
- Alex Shimmings – Deputy Managing Editor, Scrip Intelligence
- Joseph Hedden – Analyst, Datamonitor Healthcare
Thank you for listening. For any questions regarding this podcast, or our oncology analysis in general, please contact our team.
